Angelina Jolie's case highlights the importance of knowing …
Treating breast cancer almost always involves surgery, and for …
A group of more than 120 cancer researchers and physicians took…
Advertisement
FDA expands approval of Bayer cancer drug
Stivarga now OK'd to treat gastrointestinal tumors
Updated: Monday, 25 Feb 2013, 4:13 PM EST
Published : Monday, 25 Feb 2013, 4:13 PM EST
WASHINGTON (AP) - The Food and Drug Administration on Monday expanded approval of a Bayer cancer pill to treat tumors of the intestinal tract that don't respond to other treatments.
The drug is called Stivarga and regulators approved it to treat gastrointestinal stromal tumors that cannot be surgically removed and no longer respond to other FDA-approved drugs.
The FDA previously approved Stivarga to treat colorectal cancer. It works by blocking several enzymes that promote cancer growth.
The FDA approved the drug for the new use based on a study of nearly 200 patients who were randomly assigned to take Stivarga or a placebo pill.
Patients taking the drug experienced a nearly four month delay in the growth of their tumors compared to taking placebo.
The most common side effects of Stivarga in clinical trials included liver damage, severe bleeding, blistering and peeling of skin, high blood pressure, heart attacks and perforations.
Other drugs approved to treat intestinal tumors include Gleevec and Sutent, both made by Pfizer Inc.
Bayer HealthCare is a subsidiary of Germany's Bayer AG
Ground rules for posting comments: No profanity or personal attacks. No racially charged comments. If it's not something you would say to someone's face, it's most likely inappropriate. Please comment on the subject of the story itself. If you do not follow these rules, we will remove your post. Repeat offenders will be banned from making future comments. Keep it civil, folks! WANE is not responsible for the content posted in this comment section.
Email This
Print This
View Story on a Single PageAdvertisement
Advertisement
